Distribution and Viability of Peripheral Blood Mononuclear Cells from Imatinib-resistant Chronic Myeloid Leukemia Patients: an In Vitro Study

Julia Ramadhanti, Kharima Dwi Utami, Muhammad Hasan Bashari, Indra Wijaya


The incidence of Chronic Myeloid Leukemia (CML) in the world is approximately 1.5 cases per 100,000 individuals. The level of resistance to CML treatment, imatinib in Indonesia is relatively high compared to Europe. Culturing CML cells can be used as a model for the determination of pathogenesis of CML, drug efficacy testing, and drug resistance testing. Studies using CML patients’ cells to be cultured in vitro and the methods used are rarely varied. This study aims to examine the distribution and viability of peripheral blood mononuclear cells from imatinib-resistant CML patients, expected to be a reference for mononuclear cell cultures from CML patients. This study was conducted in June-August 2019 using quantitative descriptive methods. The sample was mononuclear cells isolated from peripheral blood of three imatinib-resistant CML patients at the Hemato-Oncology Polyclinic of Hasan Sadikin Hospital, each of which was cultured in vitro using RPMI 1640 for 28 days. Distribution were seen using Giemsa staining, while viability was calculated using trypan blue. Data is processed using Microsoft Excel 2013 and Graphpad. Cell viability decreased during culture. Cell distribution had a different development pattern. Blast cells, eosinophils and basophils had presentation of between 0-5%. The percentage of lymphocyte changed between 11-31%. The percentage of neutrophil changed between 16-41%. The percentage of immature cells decreased, whereas the percentage of monocyte increased. In conclusion, cell viability decreases during the culture. Distribution of cells similar to the initial condition lasted until the 7th day and in the final phase it was only dominated by monocytes.

Keywords: myeloid leukemia, chronic, cell culture, in vitro, peripheral blood mononuclear cell, cell viability.

Full Text:



Bono, S., Dello Sbarba, P., and Lulli, M., 2018, Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage, Data in Brief, 20, 1901–1904. CrossRef

Brown, B.A., 1993, Hematology: principles and procedures. 6th ed. Philadelphia: Lea & Febiger.

Bruneau, J., and Molina, T.J., 2020, WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, in T.J. Molina (ed.) Hematopathology. Cham: Springer International Publishing (Encyclopedia of Pathology), pp. 501–505. CrossRef

Cotter, S.M., 2001, Hematology. Jackson Hole, Wyo: Teton NewMedia (Quick look series in veterinary medicine).

Golde, D.W., Byers, L.A., and Cline, M.J., 1973, Chronic Myelogenous Leukemia Cell Growth and Maturation in Liquid Culture, Cancer Res., 34(2), 419-423.

Hannah, S., Nadra, I., Dransfield, I., Pryde, J.G., Rossi, A.G., and Haslett, C., 1998, Constitutive neutrophil apoptosis in culture is modulated by cell density independently of β 2 integrin- mediated adhesion, FEBS Letters, 421(2), 141–146. CrossRef

Hochhaus, A. Baccarani, M., Silver, R.T., Schiffer, C., Apperley, J.F., Cervantes, F., et al., 2020, European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia, Leukemia, 34(4), 966–984. CrossRef

Jabbour, E., and Kantarjian, H., 2022, Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring, American Journal of Hematology, 97(9), 1236–1256. CrossRef

Jabbour, E.J., Cortes, J.E., and Kantarjian, H.M., 2013, Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options, Clinical Lymphoma Myeloma and Leukemia, 13(5), 515–529. CrossRef

Jemal, A., Siegel, R., Xu, J., and Ward, E., 2010, Cancer Statistics, 2010, CA: A Cancer Journal for Clinicians, 60(5), 277–300. CrossRef

Jootar, S., 2012, CML treatment in Asia–Pacific region, Hematology, 17(sup1), s72–s74. CrossRef

Kirschnek, S., Vier, J., Gautam, S., Frankenberg, T., Rangelova, S., Eitz-Ferrer, P., et al., 2011, Molecular analysis of neutrophil spontaneous apoptosis reveals a strong role for the pro-apoptotic BH3-only protein Noxa, Cell Death & Differentiation, 18(11), 1805–1814. CrossRef

MacQueen, B.C., Henry, E., Sola-Visner, M.C., Bennett, S.T., and Christensen, R.D., 2019, Using the New Complete Blood Count Parameters in Neonatal Intensive Care Unit Practice, Hematology, Immunology and Genetics, Elsevier, pp. 75–86. CrossRef

Minciacchi, V.R., Kumar, R., and Krause, D.S., 2021, Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future, Cells, 10(1), 117. CrossRef

Osman, A.E.G., and Deininger, M.W., 2021, Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions, Blood Reviews, 49, 100825. CrossRef

Radich, J.P., Deininger, M., Abboud, C.N., Altman, J.K., Berman, E., Bhatia, R., et al., 2018, Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network, 16(9), 1108–1135. CrossRef

Reksodiputro A, H., Tadjoedin, H., Supandiman, I., Acang, N., Kar, A.S., Bakta I.M., et al., 2015, Epidemiology Study and Mutation Profile of Patients with Chronic Myeloid Leukemia (CML) in Indonesia, Journal of Blood Disorders and Transfusion, 6(3), 1000271-1000271. CrossRef

Strober, W., 2015, Trypan Blue Exclusion Test of Cell Viability, Current Protocols in Immunology, 111(1), A3.B.1–A3.B.3. CrossRef

Sumantri, A.F., Oehadian, A., Wijaya, I., Vidyaniati, P., and Rahmaniati, R., 2019, Therapeutic Responses of Imatinib and Nilotinib among CML Patients in Hasan Sadikin Hospital Bandung, Indonesian Journal of Cancer, 12(3), 88-94. CrossRef

Thompson, P.A., Kantarjian, H.M. and Cortes, J.E., 2015, Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015, Mayo Clinic Proceedings, 90(10), 1440–1454. CrossRef

Watson, R.W.G., 2002, Redox Regulation of Neutrophil Apoptosis, Antioxidants & Redox Signaling, 4(1), 97–104. CrossRef

Wong, T.W., and Jelinek, D.F., 2013, Purification of functional eosinophils from human bone marrow, Journal of Immunological Methods, 387(1–2), 130–139. CrossRef

Zuckerman, S.H., Ackerman, S.K., and Douglas, S.D., 1979, Long-term human peripheral blood monocyte cultures: establishment, metabolism and morphology of primary human monocyte-macrophage cell cultures, Immunology, 38(2), 401–411.

DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev14iss1pp22-32

Copyright (c) 2023 Indonesian Journal of Cancer Chemoprevention

Indexed by:




Indonesian Society for Cancer Chemoprevention